LONDON, UK / ACCESSWIRE / May 19, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,088,120 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 1.8288 pence per share. Following this transaction, Mr Wright has a total beneficial interest in 2,715,111 Ordinary Shares, representing approximately 0.50 per cent of the Company's issued share capital.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of PDMR/person closely associated with them ("PCA")
a)	Name	Andrew Wright
b)	Position/status	PDMR: Financial Controller and Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument	Ordinary shares of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24
b)	Nature of the transaction	Standalone acquisition of shares
c)	Price(s) and volume(s)	Price(s) Volume(s) GBP £0.018288 1,088,120
d)	Aggregated information - Aggregated volume - Price	Price(s) Volume(s) GBP £19,899.54 1,088,120
e)	Date of the transaction	2021-05-18
f)	Place of the transaction	London Stock Exchange XLON

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/648071/Hemogenyx-Pharmaceuticals-PLC-Announces-DirectorPDMR-Shareholding